iNNOVATE™: THE FIRST PHASE 3 STUDY LEADING TO FDA APPROVAL IN COMBINATION FOR WM1

iNNOVATE™: Study Design

Randomized, double-blind, placebo-controlled, phase 3 iNNOVATE™ trial1

Select Baseline Characteristics2

CXCR4=C-X-C chemokine receptor type 4, ECOG=Eastern Cooperative Oncology Group, FDA=US Food and Drug Administration, IgM=immunoglobulin M, IPSS=International Prognostic Scoring System, IRC=Independent Review Committee, L265P MYD88=myeloid differentiation primary response gene 88, PFS=progression-free survival, WM=Waldenström’s Macroglobulinemia, WT=wild type.

References: 1IMBRUVICA® (ibrutinib) Prescribing Information. 2Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med. 2018;378(25):2399-2410.